Randomized, controlled evaluation as part of INSIGhT adaptive platform trial expected to initiate around year-end 2022Study expected to assess VBI-1901...
FLORHAM PARK, N.J., Oct. 12, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a...
The sweepstakes aims to raise awareness of Deep TMS™ as a treatment option for mental health disorders so patients #DontMissAnotherMoment...
-- Approximately 100 European health care professionals invited to discuss recent scientific developments in rare pathway-related obesities -- -- Rhythm...
Suspending Development of SCS and Evaluating Alternatives for SCS AssetsHINGHAM, Mass., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Microbot Medical Inc....
Chip Wilson expands current share position and commits gross proceeds of up to $3.27 millionNOT FOR DISTRIBUTION TO U.S. NEWSWIRE...
Cannabix is developing Marijuana Breathalyzer devices to give law enforcement and employers a tool to enhance public safety Cannabix October...
JERSEY CITY, N.J., Oct. 11, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to...
Co-founder and Chairman Michael Ackermann plans to transition off Board of Directors Wendy Yarno will become Lead Independent Director and...
NEW YORK, Oct. 11, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a...
New name reflects Company focus on leveraging exclusively in-licensed foundational mRNA cell engineering patent portfolio The Eterna corporate mission is...
Las Vegas, Nevada, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a...
New Survey Focused on Access Limitations of Approved Autologous CAR T Therapies Reveals Only 50% of Eligible Cancer Patients Receive...
Data to be featured in one poster and two oral presentationsWATERTOWN, Mass., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences,...
GERMANTOWN, Md., Oct. 11, 2022 (GLOBE NEWSWIRE) -- TeraImmune, Inc., a biotechnology company focused on discovery and development of novel...
- Clinical development operations focused on ongoing Phase 2b clinical trial of AB-2004 in autism; data anticipated in 2023 -...
66% of HPV 16-positive checkpoint inhibitor refractory patients are alive at median follow up of 16 monthsFLORHAM PARK, N.J., Oct....
-Multiplex deletion of myeloid antigens CD33 and CLL-1 or CD33 and CD123 in human hematopoietic stem cells resulted in long-term...
PURCHASE, N.Y., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), announced the appointment of Paul J. Tiseo,...
FDA’s End-of-Phase 2 written response provides positive feedback related to Chemistry, Manufacturing, and Controls (CMC) to support future NDA filingSupports...